TY - JOUR
KW - Betacoronavirus
KW - Comorbidity
KW - Coronavirus Infections/complications/epidemiology/rehabilitation
KW - Humans
KW - Pandemics
KW - Pneumonia, Viral/complications/epidemiology/rehabilitation
KW - Quality of Life
KW - Severe Acute Respiratory Syndrome/epidemiology/rehabilitation
KW - Substance-Related Disorders/epidemiology/rehabilitation
KW - Telemedicine/organization & administration
KW - Addictions
KW - COVID-19
KW - harm-reduction
KW - Stigma
KW - Substance use disorder
KW - Telemedicine
AU - H. López-Pelayo
AU - H. J. Aubin
AU - C. Drummond
AU - G. Dom
AU - F. Pascual
AU - J. Rehm
AU - R. Saitz
AU - E. Scafato
AU - A. Gual
A1 - 
AB - BACKGROUND: Citizens affected by substance use disorders are high-risk populations for both SARS-CoV-2 infection and COVID-19-related mortality. Relevant vulnerabilities to COVID-19 in people who suffer substance use disorders are described in previous communications. The COVID-19 pandemic offers a unique opportunity to reshape and update addiction treatment networks. MAIN BODY: Renewed treatment systems should be based on these seven pillars: (1) telemedicine and digital solutions, (2) hospitalization at home, (3) consultation-liaison psychiatric and addiction services, (4) harm-reduction facilities, (5) person-centered care, (6) promote paid work to improve quality of life in people with substance use disorders, and (7) integrated addiction care. The three "best buys" of the World Health Organization (reduce availability, increase prices, and a ban on advertising) are still valid. Additionally, new strategies must be implemented to systematically deal with (a) fake news concerning legal and illegal drugs and (b) controversial scientific information. CONCLUSION: The heroin pandemic four decades ago was the last time that addiction treatment systems were updated in many western countries. A revised and modernized addiction treatment network must include improved access to care, facilitated where appropriate by technology; more integrated care with addiction specialists supporting non-specialists; and reducing the stigma experienced by people with SUDs.
AD - Grup Recerca Addiccions Clínic (GRAC-GRE), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic Barcelona, Rosselló 149, 08036, Barcelona, Spain. hlopez@clinic.cat.; Socidrogalcohol (Spanish Society of Drug and Alcohol Specialists), Barcelona, Spain. hlopez@clinic.cat.; Département de psychiatrie et d'addictologie, Université Paris-Saclay, Route de l'Orme aux Merisiers - RD 128 91190 Saint-Aubin, Paris, France.; Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM 1018, Paris, France.; Groupe Hospitalo-Universitaire AP-HP, Paris, France.; Addiction Psychiatry, Addictions Department, National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College, 16 De Crespigny Park, Camberwell, London, SE5 8AF, UK.; European Federation of Addiction Societies (EUFAS), 16 De Crespigny Park, Camberwell, London, SE5 8AF, UK.; Antwerp University (UA, CAPRI), Antwerp, Belgium.; Belgian Professional Psychiatry Association, Antwerp, Belgium.; European Federation of Addiction Societies (EUFAS), Antwerp, Belgium.; European Psychiatric Association (EPA), Prinsstraat 13, 2000, Antwerp, Belgium.; SOCIDROGALCOHOL, Barcelona, Spain.; CAARFE, Valencia, Spain.; Departamento de Biología Aplicada, Alicante, Spain.; UCA, Alcoy, Alicante, Spain.; Institute for Mental Health Policy Research & Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.; Dalla Lana School of Public Health and Department of Psychiatry, University of Toronto (UofT), 155 College St., Toronto, Canada.; Epidemiological Research Unit, Technische Universität Dresden, Klinische Psychologie and Psychotherapie, Dresden, Germany.; Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.; Department of Community Health Sciences (CHS), Boston University School (TRUNCATED)
BT - BMC medicine
C5 - Education & Workforce; Healthcare Disparities; HIT & Telehealth; Opioids & Substance Use
CP - 1
DO - 10.1186/s12916-020-01693-9
IS - 1
JF - BMC medicine
LA - eng
M1 - Journal Article
N2 - BACKGROUND: Citizens affected by substance use disorders are high-risk populations for both SARS-CoV-2 infection and COVID-19-related mortality. Relevant vulnerabilities to COVID-19 in people who suffer substance use disorders are described in previous communications. The COVID-19 pandemic offers a unique opportunity to reshape and update addiction treatment networks. MAIN BODY: Renewed treatment systems should be based on these seven pillars: (1) telemedicine and digital solutions, (2) hospitalization at home, (3) consultation-liaison psychiatric and addiction services, (4) harm-reduction facilities, (5) person-centered care, (6) promote paid work to improve quality of life in people with substance use disorders, and (7) integrated addiction care. The three "best buys" of the World Health Organization (reduce availability, increase prices, and a ban on advertising) are still valid. Additionally, new strategies must be implemented to systematically deal with (a) fake news concerning legal and illegal drugs and (b) controversial scientific information. CONCLUSION: The heroin pandemic four decades ago was the last time that addiction treatment systems were updated in many western countries. A revised and modernized addiction treatment network must include improved access to care, facilitated where appropriate by technology; more integrated care with addiction specialists supporting non-specialists; and reducing the stigma experienced by people with SUDs.
PY - 2020
SN - 1741-7015; 1741-7015
T1 - "The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic
T2 - BMC medicine
TI - "The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic
U1 - Education & Workforce; Healthcare Disparities; HIT & Telehealth; Opioids & Substance Use
U2 - 32731868
U3 - 10.1186/s12916-020-01693-9
VL - 18
VO - 1741-7015; 1741-7015
Y1 - 2020
Y2 - Jul 31
ER -